Vical/Astellas's TransVax first therapeutic CMV vaccine to Phase III
This article was originally published in Scrip
Executive Summary
Vical and partner Astellas have become the first firms to take an investigational therapeutic vaccine for cytomegalovirus (CMV) into a Phase III clinical study, moving their candidate TransVax (ASP0113) into a pivotal multinational program in hematopoietic stem cell transplant (HSCT) recipients.